These findings support the multifactorial benefits of HDAC inhibitor therapy, in which multiple tumorigenic pathways can be targeted with a single drug, as well as demonstrating promise for the synergistic effects of chemotherapy and HDAC inhibitors in treating GBM without development of resistance. This evidence concerns the gene HDAC9 and glioblastoma.